Protalix BioTherapeutics (Israel) Profile

ILS 0.01  0.45%
2.16Last Month High 246.7 
2.17Trading Day  High 2.29 

Protalix BioTherapeutics Summary

Protalix BioTherapeutics Inc (PLX) is traded on Tel Aviv Stock Exchange in Israel. It is located in Protalix BioTherapeutics, Inc.Carmiel, and employs 223 people. The company currently falls under 'Small-Cap' category with current market capitalization of 330.36 M. Protalix BioTherapeutics Inc has 0 outstanding shares. PROTALIX BIOTCS has accumulated about 34.53 M in cash with (27.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.26.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Protalix BioTherapeutics Risk Profiles

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings  

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 60% 
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. more
NameProtalix BioTherapeutics Inc
Macroaxis Advice
InstrumentIsrael Stock Stocks Directory
Business AddressProtalix BioTherapeutics, Inc.Carmiel,
Foreign Associate  USA
ExchangeTel Aviv Stock Exchange
Contact Number972 4 988 9488
CurrencyILS - Israeli Shekel


Protalix BioTherapeutics Corporate Directors
Roger Kornberg Independent Director, Ph.D
Amos BarShalev Independent Director, MBA
Aharon Schwartz Independent Director, Ph.D


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas